Long-term therapy with rivastigmine tartrate (Generic Exelon, Novartis), a drug that has been indicated for the treatment of mild to moderate Alzheimer’s disease, may be a treatment option for patients with sub-cortical vascular dementia, which is associated with poor blood circulation in the brain. Vascular dementia is the second most common cause of dementia after [...]
Rivastigmine tartrate (Exelon drug, Novar-tis) has been approved for patients with mild-to-moderate dementia associated with Parkinson’s disease (PD). Rivastig-mine was previously approved for the treatment of mild-to-moderate dementia of the Alzheimer’s type. Steven Galson, MD, MPH, Director of the FDA’s Center for Drug Evaluation and Research, explains that dementia associated with PD differs from dementia [...]
Novartis has received the FDA’s approval for its generic rivastigmine tartrate (Exelon drug) skin patch for patients with mild-to-moderate Alzheimer’s disease. The company said that the patch was designed with compliance in mind and was preferred to capsules by more than 70% of doctors and nurses as a method of drug delivery. The patch is [...]
